Literature DB >> 22859666

Knocking out viral myocarditis: reality or a miRage?

Xinghui Sun, Mark W Feinberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859666      PMCID: PMC3426925          DOI: 10.1161/CIRCRESAHA.112.275214

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  19 in total

1.  MicroRNA-155 is involved in the remodelling of human-trophoblast-derived HTR-8/SVneo cells induced by lipopolysaccharides.

Authors:  Yimin Dai; Zhenyu Diao; Haixiang Sun; Ruotian Li; Zhihua Qiu; Yali Hu
Journal:  Hum Reprod       Date:  2011-04-22       Impact factor: 6.918

Review 2.  The liver-specific microRNA miR-122: biology and therapeutic potential.

Authors:  Witold Filipowicz; Helge Grosshans
Journal:  Prog Drug Res       Date:  2011

3.  MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development.

Authors:  Ryan M O'Connell; Daniel Kahn; William S J Gibson; June L Round; Rebecca L Scholz; Aadel A Chaudhuri; Melissa E Kahn; Dinesh S Rao; David Baltimore
Journal:  Immunity       Date:  2010-09-30       Impact factor: 31.745

4.  Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis.

Authors:  Mamoru Satoh; Motoyuki Nakamura; Tomonari Akatsu; Junji Iwasaka; Yudai Shimoda; Ikuo Segawa; Katsuhiko Hiramori
Journal:  Clin Sci (Lond)       Date:  2003-06       Impact factor: 6.124

5.  Regulation of the germinal center response by microRNA-155.

Authors:  To-Ha Thai; Dinis Pedro Calado; Stefano Casola; K Mark Ansel; Changchun Xiao; Yingzi Xue; Andrew Murphy; David Frendewey; David Valenzuela; Jeffery L Kutok; Marc Schmidt-Supprian; Nikolaus Rajewsky; George Yancopoulos; Anjana Rao; Klaus Rajewsky
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

6.  MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis.

Authors:  Mariola Kurowska-Stolarska; Stefano Alivernini; Lucy E Ballantine; Darren L Asquith; Neal L Millar; Derek S Gilchrist; James Reilly; Michelle Ierna; Alasdair R Fraser; Bartosz Stolarski; Charles McSharry; Axel J Hueber; Derek Baxter; John Hunter; Steffen Gay; Foo Y Liew; Iain B McInnes
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

7.  microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells.

Authors:  Elena Vigorito; Kerry L Perks; Cei Abreu-Goodger; Sam Bunting; Zou Xiang; Susan Kohlhaas; Partha P Das; Eric A Miska; Antony Rodriguez; Allan Bradley; Kenneth G C Smith; Cristina Rada; Anton J Enright; Kai-Michael Toellner; Ian C M Maclennan; Martin Turner
Journal:  Immunity       Date:  2007-12-06       Impact factor: 31.745

8.  Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein.

Authors:  Li-Fan Lu; To-Ha Thai; Dinis Pedro Calado; Ashutosh Chaudhry; Masato Kubo; Kentaro Tanaka; Gabriel B Loeb; Hana Lee; Akihiko Yoshimura; Klaus Rajewsky; Alexander Y Rudensky
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

9.  Requirement of bic/microRNA-155 for normal immune function.

Authors:  Antony Rodriguez; Elena Vigorito; Simon Clare; Madhuri V Warren; Philippe Couttet; Dalya R Soond; Stijn van Dongen; Russell J Grocock; Partha P Das; Eric A Miska; David Vetrie; Klaus Okkenhaug; Anton J Enright; Gordon Dougan; Martin Turner; Allan Bradley
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

10.  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder.

Authors:  Ryan M O'Connell; Dinesh S Rao; Aadel A Chaudhuri; Mark P Boldin; Konstantin D Taganov; John Nicoll; Ronald L Paquette; David Baltimore
Journal:  J Exp Med       Date:  2008-02-25       Impact factor: 14.307

View more
  2 in total

Review 1.  Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.

Authors:  Elizabeth J Hennessy; Kathryn J Moore
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

Review 2.  Epigenetic associations in relation to cardiovascular prevention and therapeutics.

Authors:  Susanne Voelter-Mahlknecht
Journal:  Clin Epigenetics       Date:  2016-01-15       Impact factor: 6.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.